As we expand our partnership with Pfizer in the company’s most significant agreement to date, we find ourselves thinking about the CytoReason “growth factor”—the key agent to our company’s success
The Next Chapter: Harnessing Big Data with Computational Disease Models
Adding more books to your personal library gives you greater access to knowledge. But even the most dedicated bookworm can only read so much in a lifetime. This is the plight of big data in pharma.
People often characterize startups with simple analogies such as ‘Tinder for dogs’ or ‘Airbnb for parking spots.’ At CytoReason, we aim to build the Waze for the immune system – the platform for disease models.